Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomised, Cross-Over, Placebo-Controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6.

Next Previous
Search
Trial Profile

A Double-Blind, Randomised, Cross-Over, Placebo-Controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ispronicline (Primary) ; Donepezil
  • Indications Alzheimer's disease; Cognition disorders; Dementia; Vascular dementia
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 18 Apr 2009 Planned end date changed from 1 May 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Planned number of patients changed from 40 to 20 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top